eBulletin Newsletter
NCCN Flash Updates: NCCN Guidelines and Templates Updated
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Small Cell Lung Cancer.
These NCCN Guidelines® are currently available as Version 7.2024.
Link directly to the Updates section of the NCCN Guidelines: Non-Small Cell Lung Cancer
NSCL-33
- First-line Therapy
- NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy
- Repotrectinib added as a preferred treatment option
- NTRK1/2/3 gene fusion discovered during first-line systemic therapy
- Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by larotrectinib, entrectinib, or repotrectinib
- NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy
- Subsequent Therapy
- Repotrectinib added as a treatment option (if not previously given)
NSCL-J 1 of 6
- NTRK1/2/3 Gene Fusion
- First-line/Subsequent therapy
- Repotrectinib added (as per NSCL-33)
- First-line/Subsequent therapy
NSCL-J 6 of 6
- Reference 40 added: Solomon BJ, Drilon A, Lin JJ, et al. Repotrectinib in patients with NTRK fusion-positive advanced solid tumors, including non-small cell lung cancer: update from the phase 1/2 TRIDENT-1 trial. Ann Oncol. 2023;34:S787-S788.
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Non-Small Cell Lung Cancer to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v7.2024.
- Changes to the Indication section have been made on the following NCCN Template®:
- NSC134: Repotrectinib
- References have been updated on the following template:
- NSC134: Repotrectinib
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.